iBio Inc falls 22.73% amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 Dec 25
Source: Coinmarketcap
iBio Inc experienced a significant decline of 22.73%, crossing below its 5-day SMA, as broader market indices also faced losses.
This drop occurs amid a broader market weakness, with the Nasdaq-100 down 2.18% and the S&P 500 down 1.43%. The stock's movement suggests sector rotation as investors react to the overall market conditions.
The implications of this decline indicate a challenging environment for iBio Inc, as it struggles to maintain investor confidence in light of negative market trends.
Analyst Views on IBIO
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 4.75 USD with a low forecast of 2.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.230
Low
2.00
Averages
4.75
High
6.00
Current: 2.230
Low
2.00
Averages
4.75
High
6.00
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
